who is - Capital Research Associates -
http://capitalresearchassociates.co.uk/index.html
who was Dr. Sarah-Jane Richards - http://bobfiddaman.blogspot.com/2011/02/sarah-jane-richards-solicitor-was-lead.html
Wednesday, 14 March 2012
Dr. Sarah-Jane Richards - Capital Research Associates - who is - who was ....see FIDDAMAN blog
who is - Capital Research Associates -
http://capitalresearchassociates.co.uk/index.html
who was Dr. Sarah-Jane Richards - http://bobfiddaman.blogspot.com/2011/02/sarah-jane-richards-solicitor-was-lead.html
Tuesday, 13 March 2012
GSK GlaxoSmithKline antidepressant Tranylcypromine, Parnate - possible Leukemia breakthrough - FIDDAMAN blog
http://en.wikipedia.org/wiki/Tranylcypromine
http://bobfiddaman.blogspot.com/2012/03/antidepressant-may-aid.html
GlaxoSmithKline helps people to do more, feel better and live longer.
Antidepressant May Aid LeukemiaTreatment - will CCHR / Scientology / FIDDAMAN attack this life saving treatment?
Antidepressant May Aid Cancer Treatment
By Rick Nauert PhD Senior News Editor
Reviewed by John M. Grohol, Psy.D. on March 12, 2012 Researchers believe an antidepressant can work in combination with a class of chemical compounds that are related chemically to vitamin A to treat particular types of cancer.
http://psychcentral.com/news/2012/03/12/antidepressant-may-aid-cancer-treatment/35863.html
The compounds, called retinoids, are already used to treat a rare subtype of acute myeloid leukemia (AML), but the drug has not been effective for the more common types of AMLs.
In the new study, team leader Arthur Zelent, Ph.D., and colleagues have been working to unlock the potential of retinoids to treat other patients with AML. As they report in a paper published in the journal Nature Medicine, they show that the key could be an antidepressant called tranylcypromine (TCP).
“Retinoids have already transformed one rare type of fatal leukemia into a curable disease. We’ve now found a way to harness these powerful drugs to treat far more common types of leukemia,” said senior author Zelent.
“Until now, it’s been a mystery why the other forms of AML don’t respond to this drug. Our study revealed that there was a molecular block that could be reversed with a second drug that is already commonly used as an antidepressant. We think this is a very promising strategy, and if these findings can be replicated in patients the potential benefits are enormous.”
ATRA works by encouraging the leukemia cells to mature and die naturally. The team thinks the failure of AML to respond to this drug may be due to genes that ATRA normally targets becoming switched off.
In their search for a drug that could be used to reboot the activity of ATRA, the team looked to an emerging area of research called epigenetics. Epigenetic drugs do not target genes directly but instead target whether genes are switched on or off.
They discovered that inhibiting an enzyme called LSD1, using TCP, could switch these genes on again and make the cancer cells susceptible to ATRA.
The team has started a Phase II clinical trial of the drug combination in acute myeloid leukemia patients.
Co-author Kevin Petrie, Ph.D, said, “Both the retinoid ATRA and the antidepressant TCP are already available in the UK and off-patent, so these drugs should not be expensive for the health service. AML remains very difficult to treat and sadly is often fatal, with rates of the disease projected to increase significantly as the population ages, so it is particularly pleasing to have identified this new treatment approach.
“Importantly, we believe these drugs are targeting only the cancer cells and leaving normal healthy cells largely untouched, so we are hopeful that they would have fewer side-effects for patients than standard drugs. We look forward to seeing the results of the clinical trials.”
Samuel Waxman, M.D., the Founder and the Scientific Director of the Samuel Waxman Cancer Research Foundation added, “This major finding is the direct result of years of collaborative research to better understand the mechanism of action using a combination therapy of drugs that are already available on the market today, which may lead to faster cures for patients.”
By Rick Nauert PhD Senior News Editor
Reviewed by John M. Grohol, Psy.D. on March 12, 2012 Researchers believe an antidepressant can work in combination with a class of chemical compounds that are related chemically to vitamin A to treat particular types of cancer.
http://psychcentral.com/news/2012/03/12/antidepressant-may-aid-cancer-treatment/35863.html
The compounds, called retinoids, are already used to treat a rare subtype of acute myeloid leukemia (AML), but the drug has not been effective for the more common types of AMLs.
In the new study, team leader Arthur Zelent, Ph.D., and colleagues have been working to unlock the potential of retinoids to treat other patients with AML. As they report in a paper published in the journal Nature Medicine, they show that the key could be an antidepressant called tranylcypromine (TCP).
“Retinoids have already transformed one rare type of fatal leukemia into a curable disease. We’ve now found a way to harness these powerful drugs to treat far more common types of leukemia,” said senior author Zelent.
“Until now, it’s been a mystery why the other forms of AML don’t respond to this drug. Our study revealed that there was a molecular block that could be reversed with a second drug that is already commonly used as an antidepressant. We think this is a very promising strategy, and if these findings can be replicated in patients the potential benefits are enormous.”
ATRA works by encouraging the leukemia cells to mature and die naturally. The team thinks the failure of AML to respond to this drug may be due to genes that ATRA normally targets becoming switched off.
In their search for a drug that could be used to reboot the activity of ATRA, the team looked to an emerging area of research called epigenetics. Epigenetic drugs do not target genes directly but instead target whether genes are switched on or off.
They discovered that inhibiting an enzyme called LSD1, using TCP, could switch these genes on again and make the cancer cells susceptible to ATRA.
The team has started a Phase II clinical trial of the drug combination in acute myeloid leukemia patients.
Co-author Kevin Petrie, Ph.D, said, “Both the retinoid ATRA and the antidepressant TCP are already available in the UK and off-patent, so these drugs should not be expensive for the health service. AML remains very difficult to treat and sadly is often fatal, with rates of the disease projected to increase significantly as the population ages, so it is particularly pleasing to have identified this new treatment approach.
“Importantly, we believe these drugs are targeting only the cancer cells and leaving normal healthy cells largely untouched, so we are hopeful that they would have fewer side-effects for patients than standard drugs. We look forward to seeing the results of the clinical trials.”
Samuel Waxman, M.D., the Founder and the Scientific Director of the Samuel Waxman Cancer Research Foundation added, “This major finding is the direct result of years of collaborative research to better understand the mechanism of action using a combination therapy of drugs that are already available on the market today, which may lead to faster cures for patients.”
Antidepressant 'can reverse cancer cells immunity' - will FIDDAMAN & Scientology have it banned?
Antidepressant 'can reverse cancer cells immunity'
An antidepressant could be crucial in helping cancer treatment drugs reach their full potential, according to new research.
http://www.privatehealth.co.uk/news/march-2012/antidepressant-can-reverse-cancer-cells-immunity-36732/
The study by scientists at the Institute of Cancer Research found that tranylcypromine (TCP) – which can be used to treat psychotic depressive states - can make cancer cells vulnerable to the effects of a vitamin A-derivative drug called ATRA.
ATRA is already used successfully to treat a rare form of acute myeloid leukaemia (AML), but up until now, has not been effective against other types of the disease.
The drug works be creating conditions which expedite the maturity of cancer cells, meaning they die naturally in a quicker timeframe, but AML cells often have a molecular block, which can be bypassed with the use of TCP.
"We think this is a very promising strategy and if these findings can be replicated in patients the potential benefits are enormous," said senior author Arthur Zelent.
© Adfero Ltd
An antidepressant could be crucial in helping cancer treatment drugs reach their full potential, according to new research.
http://www.privatehealth.co.uk/news/march-2012/antidepressant-can-reverse-cancer-cells-immunity-36732/
The study by scientists at the Institute of Cancer Research found that tranylcypromine (TCP) – which can be used to treat psychotic depressive states - can make cancer cells vulnerable to the effects of a vitamin A-derivative drug called ATRA.
ATRA is already used successfully to treat a rare form of acute myeloid leukaemia (AML), but up until now, has not been effective against other types of the disease.
The drug works be creating conditions which expedite the maturity of cancer cells, meaning they die naturally in a quicker timeframe, but AML cells often have a molecular block, which can be bypassed with the use of TCP.
"We think this is a very promising strategy and if these findings can be replicated in patients the potential benefits are enormous," said senior author Arthur Zelent.
© Adfero Ltd
Monday, 12 March 2012
Klinefelter's - An extra female sex chromosome might actually make guys more masculine
An extra female sex chromosome might actually make guys more masculine
http://io9.com/5892334/an-extra-female-sex-chromosome-might-actually-make-guys-more-masculine
Between 1 in 500 and 1 in 1000 men have an extra X chromosome, a condition known as Klinefelter's Syndrome. In mice, these extra female genes have an unexpected effect, as the second X chromosome actually makes mice more masculine.
When researchers talk about "masculine" and "feminine" behaviors, they're typically talking about an animal's sexual behavior. And what specific behaviors might those be, pray tell? For the answer, let's go to the new paper by University of Virginia researchers to see just what happens when male mice get a second female sex chromosome:
Counter intuitively, males with two X-chromosomes were faster to ejaculate and display more ejaculations than males with a single X. Moreover, mice of both sexes with two X-chromosomes displayed increased frequencies of mounts and thrusts.
As New Scientist reports, two types of mice were used in the study. One were those with the uncommon but normal XXY chromosomal mutation. The others actually had their Y chromosome shifted to a non-sex chromosome, effectively making them male mice with XX sexual chromosomes. In both cases, the mice had the same testosterone levels as your average XY mouse, but both displayed these more masculine sexual behaviors. This suggests that sexual behaviors are determined by more than just the presence of the hormones testosterone and estrogen.
Since the researchers found the same effect in both the XX and XXY mice, we can feel pretty confident that the result is independent of the Y chromosome. Instead, whatever is making those mice act more aggressively masculine can be traced to their female sex chromosome. It's an open question whether this effect also holds true in humans, but it might well explain why a recent study found that males with Klinefelter's Syndrome tended to have more sex than other guys.
While that second X chromosome is meant to be inactive in both females and any males who happen to have it, this research supports the argument that this isn't the case - up to 25% of this supposedly latent chromosome's genes might actually be expressed. The researchers suspect that the expression of an as yet undiscovered gene is responsible for altering the sexual behavior of these mice, and how this chromosome affects the expression of genes elsewhere might help explain broader behavioral differences between the genders.
Hormones and Behavior via New Scientist. Image by Creations, via Shutterstock.
http://io9.com/5892334/an-extra-female-sex-chromosome-might-actually-make-guys-more-masculine
Between 1 in 500 and 1 in 1000 men have an extra X chromosome, a condition known as Klinefelter's Syndrome. In mice, these extra female genes have an unexpected effect, as the second X chromosome actually makes mice more masculine.
When researchers talk about "masculine" and "feminine" behaviors, they're typically talking about an animal's sexual behavior. And what specific behaviors might those be, pray tell? For the answer, let's go to the new paper by University of Virginia researchers to see just what happens when male mice get a second female sex chromosome:
Counter intuitively, males with two X-chromosomes were faster to ejaculate and display more ejaculations than males with a single X. Moreover, mice of both sexes with two X-chromosomes displayed increased frequencies of mounts and thrusts.
As New Scientist reports, two types of mice were used in the study. One were those with the uncommon but normal XXY chromosomal mutation. The others actually had their Y chromosome shifted to a non-sex chromosome, effectively making them male mice with XX sexual chromosomes. In both cases, the mice had the same testosterone levels as your average XY mouse, but both displayed these more masculine sexual behaviors. This suggests that sexual behaviors are determined by more than just the presence of the hormones testosterone and estrogen.
Since the researchers found the same effect in both the XX and XXY mice, we can feel pretty confident that the result is independent of the Y chromosome. Instead, whatever is making those mice act more aggressively masculine can be traced to their female sex chromosome. It's an open question whether this effect also holds true in humans, but it might well explain why a recent study found that males with Klinefelter's Syndrome tended to have more sex than other guys.
While that second X chromosome is meant to be inactive in both females and any males who happen to have it, this research supports the argument that this isn't the case - up to 25% of this supposedly latent chromosome's genes might actually be expressed. The researchers suspect that the expression of an as yet undiscovered gene is responsible for altering the sexual behavior of these mice, and how this chromosome affects the expression of genes elsewhere might help explain broader behavioral differences between the genders.
Hormones and Behavior via New Scientist. Image by Creations, via Shutterstock.
Saturday, 10 March 2012
Klinefelter's syndrome and psychoneurologic function
Klinefelter's syndrome and psychoneurologic function
http://molehr.oxfordjournals.org/content/16/6/425.full
http://molehr.oxfordjournals.org/content/16/6/425.full
Search for Leeds women from 1983 antidepressant drugs trial - FIDDAMAN blog reveals
Researchers are looking for women who took part in a Leeds-based trial of antidepressant drugs in 1983.
http://www.yorkshireeveningpost.co.uk/news/latest-news/top-stories/search-for-leeds-women-from-1983-antidepressant-drugs-trial-1-4313808#
The study had to be stopped after the participants suffered extreme side effects - and now experts want to know whether they had long-term problems.
Psychiatrist Prof David Healy is leading the search for the 12 women who tested the drug sertraline.
He said: “If alive, the women would be between 56 and 72. They may be living near Leeds still.”
The study was carried out by the-then Human Psychopharmacology Research Unit at the University of Leeds in 1983 on 12 healthy women then aged between 27 and 43. It was testing sertraline, a type of anti-depressant which was later launched under the brand name Zoloft.
Half of the women on the trial were given the drug and the other half had a placebo.
However the planned two-week study had to be stopped on the fourth day because of severe side effects. The results were never published.
Now Prof Healy, director of the North Wales Department of Psychological Medicine of Cardiff University, wants to find the women involved.
He said he had seen a medical report from the trial in the archive of drug company Pfizer in New York.
“The side effects that seemed most clearly linked to sertraline were apprehension, insomnia, movement disorders, and tremors,” he said.
In 2003 drugs watchdog the Medicines and Regulatory Authority issued a warning about certain types of anti-depressants, including sertraline, saying they should not be prescribed to children and young people because of an increased risk of suicidal behaviour in these age groups.
Research psychologist Dr Joanna Le Noury, who is working with Prof Healy, said they now wanted to track down the Leeds participants.
Dr Le Noury said: “The idea is to get some interviews about what went on with the study and their experiences.
“It’s also to find out how things have panned out since. Because they had a strange reaction to the drug at the time, whether they have had similar drug reactions since.”
Contact: jo.lenoury@btopenworld.com, call 01248 384452 or via: http://davidhealy.org.
http://www.yorkshireeveningpost.co.uk/news/latest-news/top-stories/search-for-leeds-women-from-1983-antidepressant-drugs-trial-1-4313808#
The study had to be stopped after the participants suffered extreme side effects - and now experts want to know whether they had long-term problems.
Psychiatrist Prof David Healy is leading the search for the 12 women who tested the drug sertraline.
He said: “If alive, the women would be between 56 and 72. They may be living near Leeds still.”
The study was carried out by the-then Human Psychopharmacology Research Unit at the University of Leeds in 1983 on 12 healthy women then aged between 27 and 43. It was testing sertraline, a type of anti-depressant which was later launched under the brand name Zoloft.
Half of the women on the trial were given the drug and the other half had a placebo.
However the planned two-week study had to be stopped on the fourth day because of severe side effects. The results were never published.
Now Prof Healy, director of the North Wales Department of Psychological Medicine of Cardiff University, wants to find the women involved.
He said he had seen a medical report from the trial in the archive of drug company Pfizer in New York.
“The side effects that seemed most clearly linked to sertraline were apprehension, insomnia, movement disorders, and tremors,” he said.
In 2003 drugs watchdog the Medicines and Regulatory Authority issued a warning about certain types of anti-depressants, including sertraline, saying they should not be prescribed to children and young people because of an increased risk of suicidal behaviour in these age groups.
Research psychologist Dr Joanna Le Noury, who is working with Prof Healy, said they now wanted to track down the Leeds participants.
Dr Le Noury said: “The idea is to get some interviews about what went on with the study and their experiences.
“It’s also to find out how things have panned out since. Because they had a strange reaction to the drug at the time, whether they have had similar drug reactions since.”
Contact: jo.lenoury@btopenworld.com, call 01248 384452 or via: http://davidhealy.org.
Wednesday, 7 March 2012
MHRA letter to press - how Daily Star misleads it's PIP readers - just like FIDDAMAN
Letter to the editor
http://www.mhra.gov.uk/NewsCentre/CON143715
FOR PUBLICATION
Sir,
The article "PIP victim hits out over secret test results" is factually incorrect. The article claims that "Test results on the now banned implants are being kept secret …". The results of the MHRA's own previous testing of PIP implants can be found on our web site under http://www.mhra.gov.uk/home/groups/dts-bs/documents/websiteresources/con140840.pdf
Further testing of the unauthorised filler has been advised by an independent expert group and is now underway. These tests will take some time to complete and the results will be evaluated by the expert group. The results will also be available on the MHRA website once completed.
Additionally, you are incorrect about the Report on PIP implants issued by the Scientific Committee on Emerging and Newly Identified Health Risks of the European Commission, which can be found on our web site http://www.mhra.gov.uk/NewsCentre/CON143575 as well as on the web site of the European Commission.
The reports referred to in Jonathan Corke's article are available to the public and I strongly suggest you correct the article. The article is misleading and could add to what is for many women a very difficult and potentially distressing time.
The Government has been clear that women – whether treated by a private clinic or not - who are concerned about their breast implants can get advice from their NHS doctor and are entitled to a free scan if they wish.
Best wishes,
Dr. Susanne Ludgate
Clinical Director
Medicines and Healthcare products Regulatory Agency (MHRA) ------------------------------------------------------------------------ 151 Buckingham Palace Road, Victoria, LONDON, SW1W 9SZ
http://www.mhra.gov.uk/NewsCentre/CON143715
FOR PUBLICATION
Sir,
The article "PIP victim hits out over secret test results" is factually incorrect. The article claims that "Test results on the now banned implants are being kept secret …". The results of the MHRA's own previous testing of PIP implants can be found on our web site under http://www.mhra.gov.uk/home/groups/dts-bs/documents/websiteresources/con140840.pdf
Further testing of the unauthorised filler has been advised by an independent expert group and is now underway. These tests will take some time to complete and the results will be evaluated by the expert group. The results will also be available on the MHRA website once completed.
Additionally, you are incorrect about the Report on PIP implants issued by the Scientific Committee on Emerging and Newly Identified Health Risks of the European Commission, which can be found on our web site http://www.mhra.gov.uk/NewsCentre/CON143575 as well as on the web site of the European Commission.
The reports referred to in Jonathan Corke's article are available to the public and I strongly suggest you correct the article. The article is misleading and could add to what is for many women a very difficult and potentially distressing time.
The Government has been clear that women – whether treated by a private clinic or not - who are concerned about their breast implants can get advice from their NHS doctor and are entitled to a free scan if they wish.
Best wishes,
Dr. Susanne Ludgate
Clinical Director
Medicines and Healthcare products Regulatory Agency (MHRA) ------------------------------------------------------------------------ 151 Buckingham Palace Road, Victoria, LONDON, SW1W 9SZ
Tuesday, 6 March 2012
Scientology Targets Kids via iPhone App - stop the CULT, stop FIDDAMAN before it's too late
A British-owned iPhone App that plays nursery rhymes to kids is being used to advertise Scientology to children in Austria.
http://austrianindependent.com/news/General_News/2012-03-02/10468/Scientology_Targets_Kids
The campaign was exposed by dad David Millar, 46, who lives in the Austrian capital Vienna and who sent a letter to local media to complain when he was asked by his six-year-old son Michael "Daddy, What is Scientology?"
Unsure where the question originated Millar had asked his son why he was asking - and discovered the US-based cult advertising on Nursery TV, an iPhone App from Rotherham-based company Music Factory Entertainment Group Ltd.
Peter Parkin, chief executive of the Yorkshire-based company, said he was shocked and disappointed and would be demanding an explanation from Google but said it was out of his control. He said: "The mechanism's that control advertising content are controlled by Google on Google AdMob, they look at browsing history and the type of App and in theory as I understand it this sort of thing should not happen.
"I will be raising it with Google immediately and asking how we can avoid it. At the end of the day it is our App and just by association people may think we are in some way endorsing this - which of course we are not. But much of what we do is for children and we are expanding our product range, we will be seeing what we can do to stop it happening again."
Dad David, who lives in the capital Vienna where he is an architect, fired off a letter to the Austrian daily newspaper Heute, saying: "My son started school this year, and enjoys reading, he saw the words pop up on the advert when he was watching Twinkle Twinkle Little Star on the 'Nursery TV' App with his younger sister - and a click later he was on the Scientology site."
Nursery TV runs three I phone Nursery rhyme TV Apps that are massively popular and its You Tube channel has notched up an incredible 127 million views. The Scientology advert was on all three Nursery Rhyme Apps for a week before David complained.
He said he was careful not to allow his kids internet access except to approved search engine sites for kids and only selected approved Apps, and was furious that the cult had managed to bypass that.
He said: "I don't care about Scientology although until recently I note they were banned here in Austria, but to have them advertising on children's TV is pretty outrageous.
"It was on Twinkle Twinkle Little Star but when you tried the other songs on the other channels it was on those as well, and stayed there all week. In the end I deleted the App.
David added: "I am British, I live in Austria and have a mobile phone with an Austrian T-mobile contract. Whatever song you chose, the Scientologists were there."
Computer expert Seth Weintraub from computerworld.com complained as long ago as 2009 about being unable to stop Scientology ads on his Google Ad Sense account but the move to target children is a new development.
In an article asking "Why is Google's AdSense doing the bidding of Scientology?" he wrote: "It appears that Scientology is in the midst of a big advertising campaign. They appear to want to advertise to my readers very much.
"But this is outrageous. Scientology is every ad block 24 hours/day for over a week now. My readers have rightfully started complaining and I'd really like Google to stop. If they are paying Google an exorbitant amount to advertise, I am not seeing any difference in my CPM rates. So, I've tried just about everything in my power to get them removed."
He said however that at the time of writing it was without success.
After further research he added that Google had removed the AdSense account of a group exposing some internal Scientology stuff and added: "Google also killed a Youtube account of an anti-Scientology crusader who was about to publish an expose on Scientology. They also removed Xenu.net, another anti-Scientology website's links.
"I don't think Google is doing the work of Scientologists. I just think they are getting a lot of cash from them and don't want to deal with their litigation tactics."
http://austrianindependent.com/news/General_News/2012-03-02/10468/Scientology_Targets_Kids
The campaign was exposed by dad David Millar, 46, who lives in the Austrian capital Vienna and who sent a letter to local media to complain when he was asked by his six-year-old son Michael "Daddy, What is Scientology?"
Unsure where the question originated Millar had asked his son why he was asking - and discovered the US-based cult advertising on Nursery TV, an iPhone App from Rotherham-based company Music Factory Entertainment Group Ltd.
Peter Parkin, chief executive of the Yorkshire-based company, said he was shocked and disappointed and would be demanding an explanation from Google but said it was out of his control. He said: "The mechanism's that control advertising content are controlled by Google on Google AdMob, they look at browsing history and the type of App and in theory as I understand it this sort of thing should not happen.
"I will be raising it with Google immediately and asking how we can avoid it. At the end of the day it is our App and just by association people may think we are in some way endorsing this - which of course we are not. But much of what we do is for children and we are expanding our product range, we will be seeing what we can do to stop it happening again."
Dad David, who lives in the capital Vienna where he is an architect, fired off a letter to the Austrian daily newspaper Heute, saying: "My son started school this year, and enjoys reading, he saw the words pop up on the advert when he was watching Twinkle Twinkle Little Star on the 'Nursery TV' App with his younger sister - and a click later he was on the Scientology site."
Nursery TV runs three I phone Nursery rhyme TV Apps that are massively popular and its You Tube channel has notched up an incredible 127 million views. The Scientology advert was on all three Nursery Rhyme Apps for a week before David complained.
He said he was careful not to allow his kids internet access except to approved search engine sites for kids and only selected approved Apps, and was furious that the cult had managed to bypass that.
He said: "I don't care about Scientology although until recently I note they were banned here in Austria, but to have them advertising on children's TV is pretty outrageous.
"It was on Twinkle Twinkle Little Star but when you tried the other songs on the other channels it was on those as well, and stayed there all week. In the end I deleted the App.
David added: "I am British, I live in Austria and have a mobile phone with an Austrian T-mobile contract. Whatever song you chose, the Scientologists were there."
Computer expert Seth Weintraub from computerworld.com complained as long ago as 2009 about being unable to stop Scientology ads on his Google Ad Sense account but the move to target children is a new development.
In an article asking "Why is Google's AdSense doing the bidding of Scientology?" he wrote: "It appears that Scientology is in the midst of a big advertising campaign. They appear to want to advertise to my readers very much.
"But this is outrageous. Scientology is every ad block 24 hours/day for over a week now. My readers have rightfully started complaining and I'd really like Google to stop. If they are paying Google an exorbitant amount to advertise, I am not seeing any difference in my CPM rates. So, I've tried just about everything in my power to get them removed."
He said however that at the time of writing it was without success.
After further research he added that Google had removed the AdSense account of a group exposing some internal Scientology stuff and added: "Google also killed a Youtube account of an anti-Scientology crusader who was about to publish an expose on Scientology. They also removed Xenu.net, another anti-Scientology website's links.
"I don't think Google is doing the work of Scientologists. I just think they are getting a lot of cash from them and don't want to deal with their litigation tactics."
Wife murderer Ragsdale was on same combo of antidepressants as FIDDAMAN - Doxepin and Paxil
http://www.ksl.com/index.php?nid=960&sid=19398820
It was determined that he was taking various medications at the time, including Concerta, pregnenolone, testosterone, Valium and the antidepressants Doxepin and Paxil. But blood toxicology reports showed David Ragsdale was within the prescribed ranges for all his medications and found no traces of any illicit substances at the time of the shooting.
see FIDDAMAN combo here -
- http://bobfiddaman.blogspot.com/2011/05/tramadol-dothiepin-seroxat-three.html
see FIDDAMAN admit that Paxil made him a danger -
- http://www.thefreelibrary.com/Letter%3A+Drug+has+made+me+a+danger.-a0118663813
note how dangerous FIDDAMAN tried to gag this blog -
- http://chillingeffects.org/N/42559
Sunday, 4 March 2012
CCHR N Zealand - withdrawing from psychiatric medication, don't contact us get a competent medical practitioner - FIDDAMAN blog reveals
WARNING: Due to serious withdrawal effects it could be dangerous to immediately cease taking psychiatric drugs. No one should stop taking any psychiatric drug without the advice and help of a competent medical practitioner.
http://www.cchr.org.nz/
http://www.cchr.org.nz/
MHRA investigate gripe water - but ignore FIDDAMAN GRIPE
Stocks of Woodward’s Gripe Water have almost dried up at supermarkets and pharmacies – leading to mothers panic buying the remaining supplies.
Until now the reason for the shortage was not clear. But yesterday the manufacturer Reckitt Benckiser confirmed production had ceased four months ago.
Bottles of the tonic, which sell in shops at £2.49, have been changing hands on eBay for up to five times the normal price.
Read more: http://www.dailymail.co.uk/news/article-2109905/UKs-best-selling-gripe-water-investigated-medicines-watchdog.html#ixzz1o8U169GT
The investigation by the Medicines and Healthcare Products Regulatory Agency (MHRA) is understood to be focusing on claims made in the written material that accompanies the bottle.
A spokesman for Reckitt Benckiser said: ‘I understand we stopped producing it last year because of some kind of licensing issues but we hope to start selling the product again in a few months.
Read more: http://www.dailymail.co.uk/news/article-2109905/UKs-best-selling-gripe-water-investigated-medicines-watchdog.html#ixzz1o8UMoQBk
For advice and support to withdraw from antidepressants please contact CCHR - says FIDDAMAN / CASPER
see bottom of page - WARNING: Sudden withdrawal from psychotropic medications can be dangerous. For advice and support to withdraw from antidepressants please contact CCHR
be sure to check out CASPER link to CCHR
Saturday, 3 March 2012
Statin Drugs - Drug Safety Communication: Class Labeling Change - be first with FIDDAMAN blog
Statin Drugs - Drug Safety Communication: Class Labeling Change
AUDIENCE: Cardiology, Family Practice, Patients
ISSUE: FDA has approved important safety label changes for the class of cholesterol-lowering drugs known as statins. The changes include removal of routine monitoring of liver enzymes from drug labels. Information about the potential for generally non-serious and reversible cognitive side effects and reports of increased blood sugar and glycosylated hemoglobin (HbA1c) levels has been added to the statin labels.
The lovastatin label has been extensively updated with new contraindications and dose limitations when it is taken with certain medicines that can increase the risk for muscle injury.
Read the FDA Drug Safety Communication for more information.
BACKGROUND: Statins are a class of prescription drugs used together with diet and exercise to reduce blood levels of low-density lipoprotein (LDL) cholesterol (“bad cholesterol”). Marketed as single-ingredient products, including Lipitor (atorvastatin), Lescol (fluvastatin), Mevacor (lovastatin), Altoprev (lovastatin extended-release), Livalo (pitavastatin), Pravachol (pravastatin), Crestor (rosuvastatin), and Zocor (simvastatin). Also marketed as combination products, including Advicor (lovastatin/niacin extended-release), Simcor (simvastatin/niacin extended-release),and Vytorin (simvastatin/ezetimibe).
RECOMMENDATION: Healthcare professionals should perform liver enzyme tests before initiating statin therapy in patients and as clinically indicated thereafter. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, therapy should be interrupted. If an alternate etiology is not found, the statin should not be restarted.
Healthcare professionals should follow the recommendations in the lovastatin label regarding drugs that may increase the risk of myopathy/rhabdomyolysis when used with lovastatin.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
Complete and submit the report Online: www.fda.gov/MedWatch/report.htm1
Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
[02/28/2012 - Drug Safety Communication2 - FDA]
[02/28/2012 - Consumer Update3 - FDA]
-
AUDIENCE: Cardiology, Family Practice, Patients
ISSUE: FDA has approved important safety label changes for the class of cholesterol-lowering drugs known as statins. The changes include removal of routine monitoring of liver enzymes from drug labels. Information about the potential for generally non-serious and reversible cognitive side effects and reports of increased blood sugar and glycosylated hemoglobin (HbA1c) levels has been added to the statin labels.
The lovastatin label has been extensively updated with new contraindications and dose limitations when it is taken with certain medicines that can increase the risk for muscle injury.
Read the FDA Drug Safety Communication for more information.
BACKGROUND: Statins are a class of prescription drugs used together with diet and exercise to reduce blood levels of low-density lipoprotein (LDL) cholesterol (“bad cholesterol”). Marketed as single-ingredient products, including Lipitor (atorvastatin), Lescol (fluvastatin), Mevacor (lovastatin), Altoprev (lovastatin extended-release), Livalo (pitavastatin), Pravachol (pravastatin), Crestor (rosuvastatin), and Zocor (simvastatin). Also marketed as combination products, including Advicor (lovastatin/niacin extended-release), Simcor (simvastatin/niacin extended-release),and Vytorin (simvastatin/ezetimibe).
RECOMMENDATION: Healthcare professionals should perform liver enzyme tests before initiating statin therapy in patients and as clinically indicated thereafter. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, therapy should be interrupted. If an alternate etiology is not found, the statin should not be restarted.
Healthcare professionals should follow the recommendations in the lovastatin label regarding drugs that may increase the risk of myopathy/rhabdomyolysis when used with lovastatin.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
Complete and submit the report Online: www.fda.gov/MedWatch/report.htm1
Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
[02/28/2012 - Drug Safety Communication2 - FDA]
[02/28/2012 - Consumer Update3 - FDA]
-
STATINS - FDA adds warnings about memory loss and blood sugar - FIDDAMAN blog latest
WASHINGTON — Federal health officials are adding new safety warnings about risks of memory loss and elevated blood sugar to statins, the most widely prescribed group of cholesterol-lowering medications.
http://www.washingtonpost.com/business/fda-adds-warnings-about-memory-loss-and-blood-sugar-to-widely-used-class-of-cholesterol-drugs/2012/02/28/gIQADiiVgR_story.html
The Food and Drug Administration said Tuesday it is making labeling changes to medicines like Pfizer Inc.’s Lipitor, AstraZeneca’s Crestor and Merck & Co. Inc.’s Zocor. The drugs are used by tens of millions of U.S. patients to help prevent heart-related problems associated with cholesterol.
New labeling on all such drugs will warn of memory loss and confusion reported among certain patients taking statins. In general the problems were not serious and went away after patients stopped taking the drugs, according to the FDA.
The updated labels will also mention elevated levels of blood sugar, associated with diabetes, that have been reported in some patients taking statins. A growing number of studies published over the last five years have found a link between statin use and type 2 diabetes. Last June, a report in the Journal of the American Medical Association analyzed five older randomized trials and concluded the increased risk was small but real for people taking higher doses of any statin.
Cardiologists said Tuesday that the lifesaving benefits of statin drugs still drastically outweigh the risks.
“Patients should not see this as a new danger with the drugs, but as a known abnormality that appears in blood testing and should be discussed with their doctor,” said Dr. Kevin Marzo, chief of cardiology at Winthrop-University Hospital in New York.
Marzo said the labeling change may lead doctors to monitor patients more closely for diabetes, especially those on high-dose statins, but he does not expect significant changes in how the drugs are prescribed. He urged patients to continue taking their medication as directed.
Statins are mainly prescribed to prevent heart attacks in people with clogged arteries and work by dramatically lowering LDL or “bad cholesterol.” They were the third best-selling drug class in the U.S. for 2010 with sales of $18.8 billion, according to health care data firm IMS Health.
In addition to the label additions, the FDA said it will remove a long-standing warning related to liver injury. The drugs label previously recommended routine testing of liver enzymes to avoid injury. The agency now recommends a single test when patients first begin taking statins.
“FDA has concluded that serious liver injury with statins is rare and unpredictable in individual patients, and that routine periodic monitoring of liver enzymes does not appear to be effective in detecting or preventing this rare side effect,” the agency said in a statement.
In addition to statins, the new labeling changes apply to several combination drugs that mix older statins with newer cholesterol medicines, including Merck’s Vytorin and Abbott Laboratories’ Simcor.
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
http://www.washingtonpost.com/business/fda-adds-warnings-about-memory-loss-and-blood-sugar-to-widely-used-class-of-cholesterol-drugs/2012/02/28/gIQADiiVgR_story.html
The Food and Drug Administration said Tuesday it is making labeling changes to medicines like Pfizer Inc.’s Lipitor, AstraZeneca’s Crestor and Merck & Co. Inc.’s Zocor. The drugs are used by tens of millions of U.S. patients to help prevent heart-related problems associated with cholesterol.
New labeling on all such drugs will warn of memory loss and confusion reported among certain patients taking statins. In general the problems were not serious and went away after patients stopped taking the drugs, according to the FDA.
The updated labels will also mention elevated levels of blood sugar, associated with diabetes, that have been reported in some patients taking statins. A growing number of studies published over the last five years have found a link between statin use and type 2 diabetes. Last June, a report in the Journal of the American Medical Association analyzed five older randomized trials and concluded the increased risk was small but real for people taking higher doses of any statin.
Cardiologists said Tuesday that the lifesaving benefits of statin drugs still drastically outweigh the risks.
“Patients should not see this as a new danger with the drugs, but as a known abnormality that appears in blood testing and should be discussed with their doctor,” said Dr. Kevin Marzo, chief of cardiology at Winthrop-University Hospital in New York.
Marzo said the labeling change may lead doctors to monitor patients more closely for diabetes, especially those on high-dose statins, but he does not expect significant changes in how the drugs are prescribed. He urged patients to continue taking their medication as directed.
Statins are mainly prescribed to prevent heart attacks in people with clogged arteries and work by dramatically lowering LDL or “bad cholesterol.” They were the third best-selling drug class in the U.S. for 2010 with sales of $18.8 billion, according to health care data firm IMS Health.
In addition to the label additions, the FDA said it will remove a long-standing warning related to liver injury. The drugs label previously recommended routine testing of liver enzymes to avoid injury. The agency now recommends a single test when patients first begin taking statins.
“FDA has concluded that serious liver injury with statins is rare and unpredictable in individual patients, and that routine periodic monitoring of liver enzymes does not appear to be effective in detecting or preventing this rare side effect,” the agency said in a statement.
In addition to statins, the new labeling changes apply to several combination drugs that mix older statins with newer cholesterol medicines, including Merck’s Vytorin and Abbott Laboratories’ Simcor.
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
GPs face pressure to reduce antidepressant prescribing - FIDDAMAN blog reveals
GPs face pressure to reduce antidepressant prescribing
By Beatrice Baiden
02 Mar 2012
GPs will come under increasing pressure not to prescribe antidepressants, after new NHS guidance urged a reduction in antidepressant drug use to save money.
The new guidance - published by the National Prescribing Centre - is designed to maximise efficiency savings in 2012/13 and calls for commissioners to focus on prescribing costs for treatments for depression.
The QIPP document states: ‘NICE advocates a stepwise approach to the management of common mental health disorders, offering or referring for the least intrusive, most effective intervention first.'
‘Therefore, for many people with depression or general anxiety disorder, non-drug interventions (such as cognitive behavioural therapy) should be the mainstay of treatment, with drugs generally being reserved for more severe illness or when symptoms have failed to respond to non-drug interventions.'
The guidance also encourages commissioners to ensure that generic SSRIs are the preferred treatment for patients with depression or anxiety.
But Dr Jonty Heaversedge, a GP in south east London with a special interest in mental health, said the first line treatment of patients with depression should depend on severity and patient choice.
He said: ‘Some patients do not want non-pharmacological treatment and request medical treatment specifically.'
He added: ‘If the guidance comes into practice it could lead to a significant increase in patients referred for psychological treatment, services need to have resources to meet the demand. I am not sure they would.'
Professor Dick Churchill, clinical associate professor at the University of Nottingham, said the guidance was well supported by evidence, but the lack of availability to psychological therapies would hamper its application.
‘Patients with depression can, in practice, sometimes find it difficult to initiate the contacts with psychological services before they have had pharmacological interventions,' he said.
The document also recommends commissioners ensure GPs use minocycline less for treating patients with acne. However, Dr Stephen Kownacki, executive chair of the Primary Care Dermatology said although he was in favour of the recommendations, there were few alternatives.
He said tetracycline and oxytetracycline were ‘absorbed very badly' and ‘have problems with compliance' due to their twice-daily regimen.
http://www.pulsetoday.co.uk/newsarticle-content/-/article_display_list/13560057/gps-face-pressure-to-reduce-antidepressant-prescribing
By Beatrice Baiden
02 Mar 2012
GPs will come under increasing pressure not to prescribe antidepressants, after new NHS guidance urged a reduction in antidepressant drug use to save money.
The new guidance - published by the National Prescribing Centre - is designed to maximise efficiency savings in 2012/13 and calls for commissioners to focus on prescribing costs for treatments for depression.
The QIPP document states: ‘NICE advocates a stepwise approach to the management of common mental health disorders, offering or referring for the least intrusive, most effective intervention first.'
‘Therefore, for many people with depression or general anxiety disorder, non-drug interventions (such as cognitive behavioural therapy) should be the mainstay of treatment, with drugs generally being reserved for more severe illness or when symptoms have failed to respond to non-drug interventions.'
The guidance also encourages commissioners to ensure that generic SSRIs are the preferred treatment for patients with depression or anxiety.
But Dr Jonty Heaversedge, a GP in south east London with a special interest in mental health, said the first line treatment of patients with depression should depend on severity and patient choice.
He said: ‘Some patients do not want non-pharmacological treatment and request medical treatment specifically.'
He added: ‘If the guidance comes into practice it could lead to a significant increase in patients referred for psychological treatment, services need to have resources to meet the demand. I am not sure they would.'
Professor Dick Churchill, clinical associate professor at the University of Nottingham, said the guidance was well supported by evidence, but the lack of availability to psychological therapies would hamper its application.
‘Patients with depression can, in practice, sometimes find it difficult to initiate the contacts with psychological services before they have had pharmacological interventions,' he said.
The document also recommends commissioners ensure GPs use minocycline less for treating patients with acne. However, Dr Stephen Kownacki, executive chair of the Primary Care Dermatology said although he was in favour of the recommendations, there were few alternatives.
He said tetracycline and oxytetracycline were ‘absorbed very badly' and ‘have problems with compliance' due to their twice-daily regimen.
http://www.pulsetoday.co.uk/newsarticle-content/-/article_display_list/13560057/gps-face-pressure-to-reduce-antidepressant-prescribing
Victory for Google as top judge rules it can't be held responsible for defamatory blog posts
Victory for Google as top judge rules it can't be held responsible for defamatory blog posts
Read more: http://www.dailymail.co.uk/news/article-2109349/Google-victory-judge-rules-held-responsible-defamatory-blog-posts.html#ixzz1o2jleWz9
A High Court judge has likened Google to a graffiti strewn wall in a landmark judgement which says it cannot be held responsible for libellous or offensive content.
Mr Justice Eady said the internet giant was not bound by laws governing publishers, giving the company widespread immunity from English defamation laws.
In the judgement, which will have huge implications for freedom of speech in this country, he said: ‘It is no doubt often true that the owner of a wall which has been festooned, overnight, with defamatory graffiti could acquire scaffolding and have it all deleted with whitewash.’
Defeat: Payam Tamiz, left, lost his case against Google after Mr Justice Eady, right, ruled it could not be held responsible for offensive blog posts
But he added: ‘That is not necessarily to say, however, that the unfortunate owner must, unless and until this has been accomplished, be classified as a publisher’.
The ruling came at the end of a long running defamation suit taken by a former Conservative Party hopeful and law student Payam Tamiz.
Read more: http://www.dailymail.co.uk/news/article-2109349/Google-victory-judge-rules-held-responsible-defamatory-blog-posts.html#ixzz1o2kJslXS
Read more: http://www.dailymail.co.uk/news/article-2109349/Google-victory-judge-rules-held-responsible-defamatory-blog-posts.html#ixzz1o2jleWz9
A High Court judge has likened Google to a graffiti strewn wall in a landmark judgement which says it cannot be held responsible for libellous or offensive content.
Mr Justice Eady said the internet giant was not bound by laws governing publishers, giving the company widespread immunity from English defamation laws.
In the judgement, which will have huge implications for freedom of speech in this country, he said: ‘It is no doubt often true that the owner of a wall which has been festooned, overnight, with defamatory graffiti could acquire scaffolding and have it all deleted with whitewash.’
Defeat: Payam Tamiz, left, lost his case against Google after Mr Justice Eady, right, ruled it could not be held responsible for offensive blog posts
But he added: ‘That is not necessarily to say, however, that the unfortunate owner must, unless and until this has been accomplished, be classified as a publisher’.
The ruling came at the end of a long running defamation suit taken by a former Conservative Party hopeful and law student Payam Tamiz.
Read more: http://www.dailymail.co.uk/news/article-2109349/Google-victory-judge-rules-held-responsible-defamatory-blog-posts.html#ixzz1o2kJslXS
Friday, 2 March 2012
Scientists shocked to find antibiotics alleviate symptoms of schizophrenia - FIDDAMAN blog reveals
A cheap antibiotic normally prescribed to teenagers for acne is to be tested as a treatment to alleviate the symptoms of psychosis in patients with schizophrenia, in a trial that could advance scientific understanding of the causes of mental illness.
http://www.independent.co.uk/news/science/scientists-shocked-to-find-antibiotics-alleviate-symptoms-of-schizophrenia-7469121.html
The National Institute for Health Research is funding a £1.9m trial of minocycline, which will begin recruiting patients in the UK next month. The research follows case reports from Japan in which the drug was prescribed to patients with schizophrenia who had infections and led to dramatic improvements in their psychotic symptoms.
The chance observation caused researchers to test the drug in patients with schizophrenia around the world. Trials in Israel, Pakistan and Brazil have shown significant improvement in patients treated with the drug.
Scientists believe that schizophrenia and other mental illnesses including depression and Alzheimer's disease may result from inflammatory processes in the brain. Minocycline has anti-inflammatory and neuroprotective effects which they believe could account for the positive findings.
Details of the trial were presented to the independent Schizophrenia Commission by Bill Deakin, professor of psychiatry at the University of Manchester, who is the lead investigator. The 12-member commission, set up by the mental health charity Rethink, is looking into the treatment and care of people with schizophrenia, and is due to report in the summer.
The first account of minocycline's effects appeared in 2007 when a 23-year-old Japanese man was admitted to hospital suffering from persecutory delusions and paranoid ideas. He had no previous psychiatric history but became agitated and suffered auditory hallucinations, anxiety and insomnia.
Blood tests and brain scans showed no abnormality and he was started on the powerful anti-psychotic drug halperidol. The treatment had no effect and he was still suffering from psychotic symptoms a week later when he developed severe pneumonia.
He was prescribed minocycline to treat the pneumonia and within two weeks the infection was cleared and the psychosis resolved. Minocycline was stopped and his psychiatric symptoms worsened. Treatment with the drug was resumed and within three days he was better again. Halperidol was reduced but he remained on minocycline. Two years after his psychotic episode, he was still well.
The UK trial aims to recruit 175 patients recently diagnosed with schizophrenia, half of whom will be randomly allocated to take minocycline with their standard anti-psychotic treatment while the remainder take a placebo.
Brain scans will be carried out at the start and end of the 12 month trial to compare loss of grey matter – an effect of schizophrenia – in the two groups. Tests will also measure inflammatory markers in the blood.
Professor Sir Robin Murray, chair of the Schizophrenia Commission said: "Infection or inflammation might be involved in a minority of people with acute psychosis and minocycline might counter this. In depression inflammatory markers go up and in Alzheimer's too."
Jeremy Laurance is a member of the Schizophrenia Commission
Subscribe to:
Posts (Atom)